Comparative evaluation of tigecycline susceptibility testing methods for expanded-spectrum cephalosporin- and carbapenem-resistant gram-negative pathogens

Journal of Clinical Microbiology

Volumn 50, Issue 11, 2012, Pages 3747-3750

  Zarkotou, Olympia ^a   Pournaras, Spyros ^b   Altouvas, George ^a   Pitiriga, Vassiliki ^c   Tziraki, Maria ^a   Mamali, Vassiliki ^a   Themeli Digalaki, Katerina ^a   Tsakris, Athanassios ^c  

^a TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; BETA LACTAMASE OXA 48; BETA LACTAMASE OXA 58; BETA LACTAMASE VIM; CARBAPENEM; CARBAPENEMASE; CEPHALOSPORIN; EXTENDED SPECTRUM BETA LACTAMASE; METALLO BETA LACTAMASE; TIGECYCLINE; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; AGAR MEDIUM; ANALYTICAL ERROR; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BROTH DILUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENTEROBACTER; ENTEROBACTERIACEAE; EPSILOMETER TEST; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GREECE; INTERMETHOD COMPARISON; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TEST STRIP;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CARBAPENEMS; CEPHALOSPORINS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE;

EID: 84867487596     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02037-12     Document Type: Article

References (24)

1. Bolmström A, et al. 2007. Validation and reproducibility assessment of tigecycline MIC determinations by Etest. J. Clin. Microbiol. 45:2474-2479. (Pubitemid 47295476)
2. Carmeli Y, et al. 2010. Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. Clin. Microbiol. Infect. 16:102-111.
3. Casal M, et al. 2009. Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacterspp. J. Antimicrob. Chemother. 64:69-72.
4. Castanheira MH, Sader S, Deshpande LM, Fritsche TR, Jones RN. 2008. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother. 52: 570-573. (Pubitemid 351170830)
5. Clinical and Laboratory Standards Institute. 2008. Development of in vitro susceptibility testing criteria and quality control parameters, 3d edition. M23-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Clinical and Laboratory Standards Institute. 2008. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th edition. M08-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Cohen Stuart J, et al. 2010. Evaluation of Etest to determine tigecycline MICs for Enterobacter species. Antimicrob. Agents Chemother. 54:2746-2747.
8. European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2012. Breakpoint tables for interpretation of MICs and zone diameters. Version 2.0, valid from 2012-01-01. http://www.eucast.org/clinical-breakpoints/.
9. Falagas ME, Karageorgopoulos DE, Nordmann P. 2011. Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes. Future Microbiol. 6:653-666.
10. Hope R, et al. 2010. Tigecycline activity: low resistance rates but problematic disc breakpoints revealed by a multicentre sentinel survey in the UK. J. Antimicrob. Chemother. 65:2602-2609.
11. International Organization for Standardization. 2007. ISO 20776-2: 2007(E). Clinical laboratory testing and in vitro diagnostic test systems. Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices. Part 2: evaluation of performance of antimicrobial susceptibility test devices. International Organization for Standardization, Geneva, Switzerland.
12. Jones RN, et al. 2007. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J. Clin. Microbiol. 45:227-230. (Pubitemid 46106432)
13. Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME. 2008. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J. Antimicrob. Chemother. 62:895-904.
14. Kulah C, et al. 2009. Unexpected tigecycline resistance among Acinetobacterbaumannii isolates: high minor error rate by Etest. J. Chemother. 21:390-395.
15. Lat A, et al. 2011. Comparison of polymyxin B, tigecycline, cefepime, and meropenem MICs for KPC-producing Klebsiella pneumoniae by broth microdilution, Vitek2, and Etest. J. Clin. Microbiol. 49:1795-1798.
16. Mendes RE, Farrell DJ, Sader HS, Jones RN. 2010. Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005-2009). Diagn. Microbiol. Infect. Dis. 68:307-311.
17. Miyakis S, Pefanis A, Tsakris A. 2011. The challenges of antimicrobial drug resistance in Greece. Clin. Infect. Dis. 53:177-184.
18. Nordmann P, Naas T, Poirel L. 2011. Global spread of carbapenemase- producing Enterobacteriaceae. Emerg. Infect. Dis. 17:1791-1798.
19. Pillar CM, Draghi DC, Dowzicky MJ, Sahm DF. 2008. In vitro activity of tigecycline against gram-positive and gram-negative pathogens as evaluated by broth microdilution and Etest. J. Clin. Microbiol. 46:2862-2867.
20. Pournaras S, et al. 2009. Clonal spread of KPC-2 carbapenemase-producing Klebsiella pneumoniae strains in Greece. J. Antimicrob. Chemother. 64:348-352.
21. Sader HS, Farrell DJ, Jones RN. 2011. Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005-2009). Diagn. Microbiol. Infect. Dis. 69:223-227.
22. Torrico M, et al. 2010. Influence of media and testing methodology on susceptibility to tigecycline of Enterobacteriaceae with reported high tigecycline MIC. J. Clin. Microbiol. 48:2243-2246.
23. Tsakris A, et al. 2010. A simple phenotypic method for the differentiation of metallo-beta-lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates. J. Antimicrob. Chemother. 65:1664-1671.
24. Wyeth Pharmaceuticals Inc. 2005. Tygacil package insert. Wyeth Pharmaceuticals Inc., Philadelphia, PA.